达拉非尼联合曲美替尼用于24例恶性黑色素瘤辅助治疗的回顾性分析

贾东东; 李涛

doi:10.19401/j.cnki.1007-3639.2022.12.005

您当前的位置：

首页 >

文章列表页 >

达拉非尼联合曲美替尼用于24例恶性黑色素瘤辅助治疗的回顾性分析

专题论著 | 更新时间：2025-12-31

- 达拉非尼联合曲美替尼用于24例恶性黑色素瘤辅助治疗的回顾性分析
- Retrospective analysis of adjuvant therapy with dabrafenib and trametinib for 24 patients with malignant melanoma
- 中国癌症杂志 2022年32卷第12期页码：1178-1183
- 作者机构：
  
  中国科学院大学附属肿瘤医院（浙江省肿瘤医院）骨与软组织肿瘤外科，中国科学院基础医学与肿瘤研究所，浙江杭州 310005
- 作者简介：
  
  [ "贾东东（ORCID：0000-0002-6804-4988）。" ]
  [ "李涛，医学博士，主任医师，教授。现任中国科学院大学附属肿瘤医院（浙江省肿瘤医院）骨与软组织肿瘤外科主任，浙江省癌症中心恶性黑色素瘤诊治中心主任。担任中国抗癌协会肉瘤专业委员会常委、软组织肿瘤学组副组长，中国抗癌协会皮肤肿瘤专业委员会常委，浙江省抗癌协会皮肤肿瘤专业委员会主任委员，浙江省抗癌协会骨与软组织肿瘤专业委员会副主任委员，中国继续医学教育协会骨与软组织肿瘤专业委员会常委等。荣获浙江省高层次创新人才称号。此外担任《皮肤及肢端恶性黑色素瘤外科诊治中国专家共识》主编，《中国软组织肿瘤专家共识》《中国临床肿瘤学会CSCO常见恶性肿瘤诊疗指南》编委。擅长各种骨与软组织良恶性肿瘤的治疗，包括骨恶性肿瘤的关节置换等保肢手术，软组织肉瘤的广泛切除及术后缺损的各种肌皮瓣转移修复重建，骨盆、骶骨肿瘤切除及功能重建，脊柱转移癌的手术及综合治疗等。" ]
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2022.12.005
  中图分类号： R739.5
- 收稿：2022-11-09，
  
  修回：2022-12-01，
  
  纸质出版：2022-12-30
- 稿件说明：
移动端阅览
贾东东, 李涛. 达拉非尼联合曲美替尼用于24例恶性黑色素瘤辅助治疗的回顾性分析[J]. 中国癌症杂志, 2022,32(12):1178-1183.

Dongdong JIA, Tao LI. Retrospective analysis of adjuvant therapy with dabrafenib and trametinib for 24 patients with malignant melanoma[J]. China Oncology, 2022, 32(12): 1178-1183.
贾东东, 李涛. 达拉非尼联合曲美替尼用于24例恶性黑色素瘤辅助治疗的回顾性分析[J]. 中国癌症杂志, 2022,32(12):1178-1183. DOI： 10.19401/j.cnki.1007-3639.2022.12.005.

Dongdong JIA, Tao LI. Retrospective analysis of adjuvant therapy with dabrafenib and trametinib for 24 patients with malignant melanoma[J]. China Oncology, 2022, 32(12): 1178-1183. DOI： 10.19401/j.cnki.1007-3639.2022.12.005.

摘要

背景与目的：

恶性黑色素瘤是最致命的皮肤恶性肿瘤。Ⅲ期黑色素瘤术后复发的风险相对较高，本文回顾性分析了达拉非尼联合曲美替尼作为辅助治疗对携带有

BRAF

突变的中国Ⅲ期恶性黑色素瘤患者的疗效及安全性。

方法：

回顾性分析2019年8月—2022年4月在浙江省肿瘤医院收治的24例接受曲美替尼联合达拉非尼辅助治疗的Ⅲ期皮肤及肢端恶性黑色素瘤的患者。

结果：

在24例患者中，7例为黑色素瘤ⅢB期，11例为ⅢC期，3例为ⅢD期，3例为Ⅲ期（具体分期不明）。截至2022年10月1日，有12例（50.0%）患者完成了1年的辅助治疗。全部24例患者中有5例（20.8%）报告肿瘤复发。1年无复发生存（relapse-free survival，RFS）率为76.2%（95% CI：65.2% ~ 87.2%）。在皮肤黑色素瘤亚组中，1年RFS率为81.6%（95% CI：71.6% ~ 91.6%）。2例在辅助治疗期间复发，3例患者在完成治疗方案后复发。20例患者（83.3%）报告了至少一次不良事件，其中7例患者（29.2%）发生了3级或4级的严重不良反应。最常见的不良反应是发热、疲劳和恶心。有4例患者发生了脂膜炎，主要累及大腿及上肢。1例患者（4.2%）因不良事件导致永久停药，2例患者（8.3%）因不良事件导致剂量调整，7例患者（29.2%）因不良事件导致用药中断。

结论：

本研究结果显示，达拉非尼联合曲美替尼辅助治疗可使

BRAF

V600

突变的Ⅲ期黑色素瘤患者短期获益，耐受性良好。

Abstract

Background and purpose:

Melanoma is the most lethal cutaneous malignant tumor. Patients with resected stage Ⅲ melanomas have a high risk of recurrence after surgery. This study retrospectively analyzed the efficacy and safety of dabrafenib combined with trametinib in the adjuvant setting for stage Ⅲ melanoma patients with BRAF mutation in China.

Methods:

A retrospective analysis was performed on 24 patients with stage Ⅲ cutaneous and acral malignant melanoma who received adjuvant treatment with trametinib and dabrafenib in Zhejiang Cancer Hospital from August 2019 to April 2022.

Results:

Of the 24 patients

7 were stage Ⅲ B

11 were stage Ⅲ C

3 were stage Ⅲ D

and 3 were stage Ⅲ (the specific stage was unknown). As of October 1

2022

12 patients (50.0%) had completed the protocol for one year. Of the 24 patients

5 (20.8%) patients relapsed. The The 1-year recurrence-free survival (RFS) rate was 76.2% (95% CI: 65.2%-87.2%). In the cutaneous melanoma subgroup

the 1-year RFS rate was 81.6% (95% CI: 71.6%-91.6%). Two patients relapsed during adjuvant therapy

and three patients relapsed after completing the

protocol. Twenty patients (83.3%) reported at least one adverse event

of which 7 patients (29.2%) had grade 3 or grade 4 serious adverse reactions. The most common adverse reactions were fever

fatigue and nausea. Panniculitis occurred in 4 patients

mainly involving thighs and upper limbs. One patient (4.2%) permanently stopped taking the drug due to adverse events

the dose was adjusted in 2 patients (8.3%) due to adverse events

and drug treatment was interrupted in 7 patients (29.2%) due to adverse events.

Conclusion:

This study confirmed the short-term benefit and good tolerance of the adjuvant therapy with dabrafenib combined with trametinib in Chinese patients with stage Ⅲ melanoma with

BRAF

V600

mutation.

关键词

Keywords

references

CHEN W Q , ZHENG R S , BAADE P D , et al . Cancer statistics in China, 2015 [J ] . CA Cancer J Clin , 2016 , 66 ( 2 ): 115 - 132 . DOI: 10.3322/caac.21338 http://doi.org/10.3322/caac.21338 http://doi.wiley.com/10.3322/caac.21338 http://doi.wiley.com/10.3322/caac.21338

GUO J , QIN S K , LIANG J , et al . Chinese guidelines on the diagnosis and treatment of melanoma (2015 edition) [J ] . Chin Clin Oncol , 2016 , 5 ( 4 ): 57 . DOI: 10.21037/cco.2015.12.02 http://doi.org/10.21037/cco.2015.12.02

MAURER G , TARKOWSKI B , BACCARINI M . Raf kinases in cancer-roles and therapeutic opportunities [J ] . Oncogene , 2011 , 30 ( 32 ): 3477 - 3488 . DOI: 10.1038/onc.2011.160 http://doi.org/10.1038/onc.2011.160

NIAULT T S , BACCARINI M . Targets of RAF in tumorigenesis [J ] . Carcinogenesis , 2010 , 31 ( 7 ): 1165 - 1174 . DOI: 10.1093/carcin/bgp337 http://doi.org/10.1093/carcin/bgp337

ASCIERTO P A , KIRKWOOD J M , GROB J J , et al . The role of BRAF V600 mutation in melanoma [J ] . J Transl Med , 2012 , 10 : 85 . DOI: 10.1186/1479-5876-10-85 http://doi.org/10.1186/1479-5876-10-85

BARBOUR A P , TANG Y H , ARMOUR N , et al . BRAF mutation status is an independent prognostic factor for resected stage ⅢB and ⅢC melanoma: implications for melanoma staging and adjuvant therapy [J ] . Eur J Cancer , 2014 , 50 ( 15 ): 2668 - 2676 . DOI: 10.1016/j.ejca.2014.06.009 http://doi.org/10.1016/j.ejca.2014.06.009 https://linkinghub.elsevier.com/retrieve/pii/S0959804914007539 https://linkinghub.elsevier.com/retrieve/pii/S0959804914007539

SI L , KONG Y , XU X W , et al . Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort [J ] . Eur J Cancer , 2012 , 48 ( 1 ): 94 - 100 . DOI: 10.1016/j.ejca.2011.06.056 http://doi.org/10.1016/j.ejca.2011.06.056

LONG G V , STROYAKOVSKIY D , GOGAS H , et al . Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma [J ] . N Engl J Med , 2014 , 371 ( 20 ): 1877 - 1888 . DOI: 10.1056/NEJMoa1406037 http://doi.org/10.1056/NEJMoa1406037 http://www.nejm.org/doi/10.1056/NEJMoa1406037 http://www.nejm.org/doi/10.1056/NEJMoa1406037

ROBERT C , KARASZEWSKA B , SCHACHTER J , et al . Improved overall survival in melanoma with combined dabrafenib and trametinib [J ] . N Engl J Med , 2015 , 372 ( 1 ): 30 - 39 . DOI: 10.1056/NEJMoa1412690 http://doi.org/10.1056/NEJMoa1412690 http://www.nejm.org/doi/10.1056/NEJMoa1412690 http://www.nejm.org/doi/10.1056/NEJMoa1412690

SI L , ZHANG X S , SHIN S J , et al . Open-label, phase Ⅱa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma [J ] . Eur J Cancer , 2020 , 135 : 31 - 38 . DOI: 10.1016/j.ejca.2020.04.044 http://doi.org/10.1016/j.ejca.2020.04.044 https://linkinghub.elsevier.com/retrieve/pii/S0959804920302495 https://linkinghub.elsevier.com/retrieve/pii/S0959804920302495

AMAGAI R , MUTO Y , KATO H , et al . Retrospective analysis of adjuvant therapy using dabrafenib plus trametinib in Japanese patients with advanced melanoma: analysis of 36 cases [J ] . Melanoma Res , 2021 , 31 ( 6 ): 575 - 578 . DOI: 10.1097/CMR.0000000000000770 http://doi.org/10.1097/CMR.0000000000000770

LONG G V , HAUSCHILD A , SANTINAMI M , et al . Adjuvant dabrafenib plus trametinib in stage Ⅲ BRAF-mutated melanoma [J ] . N Engl J Med , 2017 , 377 ( 19 ): 1813 - 1823 . DOI: 10.1056/NEJMoa1708539 http://doi.org/10.1056/NEJMoa1708539 http://www.nejm.org/doi/10.1056/NEJMoa1708539 http://www.nejm.org/doi/10.1056/NEJMoa1708539

DUMMER R , HAUSCHILD A , SANTINAMI M , et al . Five-year analysis of adjuvant dabrafenib plus trametinib in stage Ⅲ melanoma [J ] . N Engl J Med , 2020 , 383 ( 12 ): 1139 - 1148 . DOI: 10.1056/NEJMoa2005493 http://doi.org/10.1056/NEJMoa2005493 http://www.nejm.org/doi/10.1056/NEJMoa2005493 http://www.nejm.org/doi/10.1056/NEJMoa2005493

EGGERMONT A M M , BLANK C U , MANDALA M , et al . Adjuvant pembrolizumab versus placebo in resected stage Ⅲ melanoma [J ] . N Engl J Med , 2018 , 378 ( 19 ): 1789 - 1801 . DOI: 10.1056/NEJMoa1802357 http://doi.org/10.1056/NEJMoa1802357 http://www.nejm.org/doi/10.1056/NEJMoa1802357 http://www.nejm.org/doi/10.1056/NEJMoa1802357

YOKOTA K , UCHI H , UHARA H , et al . Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage Ⅲ/Ⅳ melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study [J ] . J Dermatol , 2019 , 46 ( 12 ): 1197 - 1201 . DOI: 10.1111/1346-8138.15103 http://doi.org/10.1111/1346-8138.15103 https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.15103 https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.15103

LI T , JIA D D , TENG L S . Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage Ⅲ melanoma: a retrospective cohort study [J ] . Invest New Drugs , 2020 , 38 ( 5 ): 1334 - 1341 . DOI: 10.1007/s10637-020-00913-6 http://doi.org/10.1007/s10637-020-00913-6 https://doi.org/10.1007/s10637-020-00913-6 https://doi.org/10.1007/s10637-020-00913-6

LI J J , WANG J H , LI D D , et al . Adjuvant PD-1 inhibitor versus high-dose interferon α-2b for Chinese patients with cutaneous and acral melanoma: a retrospective cohort analysis [J ] . Dermatol Ther , 2021 , 34 ( 5 ): e15067.

SI L , ZHANG X S , SHU Y Q , et al . A phase Ⅰb study of pembrolizumab as second-line therapy for Chinese patients with advanced or metastatic melanoma (KEYNOTE-151) [J ] . Transl Oncol , 2019 , 12 ( 6 ): 828 - 835 . DOI: 10.1016/j.tranon.2019.02.007 http://doi.org/10.1016/j.tranon.2019.02.007 https://linkinghub.elsevier.com/retrieve/pii/S1936523318305916 https://linkinghub.elsevier.com/retrieve/pii/S1936523318305916

RIBAS A , HAMID O , DAUD A , et al . Association of pembrolizumab with tumor response and survival among patients with advanced melanoma [J ] . JAMA , 2016 , 315 ( 15 ): 1600 - 1609 . DOI: 10.1001/jama.2016.4059 http://doi.org/10.1001/jama.2016.4059

MAO L L , DING Y , BAI X , et al . Overall survival of patients with unresectable or metast atic BRAF V600-mutant acral/cutaneous melanoma administered dabrafenib plus trametinib: long-term follow-up of a multicenter, single-arm phase Ⅱa trial [J ] . Front Oncol , 2021 , 11 : 720044.

CONSOLI F , MANGANONI A M , GRISANTI S , et al . Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: potential predictive role of treatment efficacy [J ] . PLoS One , 2019 , 14 ( 4 ): e0214884.

浏览量

2349

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

白蛋白结合型紫杉醇联合吉西他滨动脉灌注治疗进展期胰腺癌的安全性和有效性回顾性研究

紫杉醇脂质体联合顺铂对比吉西他滨联合顺铂一线治疗伴有区域淋巴结转移的晚期非小细胞肺癌的临床研究

着丝粒蛋白A驱动的染色体不稳定性与乳腺癌相关性研究的进展及展望：机制、预后及临床靶向治疗应用

靶向治疗及免疫治疗联合化疗为产AFP阳性结肠癌患者带来显著获益1例病例报告并文献复习

转移性结直肠癌三线治疗的研究现状及进展